. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Best Pract Res Clin Haematol. 2019 Feb 7;32(1):74–88. doi: 10.1016/j.beha.2019.02.002

Table 1.

SLE and hematologic malignancy risk

Ref	No. of patients	Cases	Malignancy type	Calculated risk (95% CI)
Lofstrom et al(96)	6438 patients	8	AML	For Azathioprine: 0.8(0.1-4.1) For leukopenia: 14 (1.4-141)
Bernatsky et al(80)	16409 patients over 7.4 person-years	18	leukemia	For hematologic malignancies: SIR 3.02(2.48-3.63) For leukemia: SIR 1.75 (1.04-2.76)
Tarr et al(88)	860 patients	5	hematologic malignancies	For hematologic malignancies: SIR of 1.31, 95% CI 0.424–3.071
Bjornadal et al(84)	5715 patients over 30-year observation period	Not available	myeloid leukemia	For acute myeloid leukemia, SIR for 1–5 years, 5–10 years and 10–15 years SLE latency were 6.1 (95% CI 2.0–14.1), 1.3 (95% CI 0.0–7.4) and 4.1 (95 CI 0.5–14.6),
Parikh-Patel et al(101)	30,478 patients observed for 157,969 person-years	29	myeloid leukemia	For myeloid leukemia, SIR 2.96 (1.99-4.26).
Chen et al(100)	11,763 patients	7	leukemia	For hematologic malignancies: SIR 4.96; 95% CI 4.79-5.14 For leukemia: SIR 2.64 (2.45-2.84)